UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 155 filers reported holding UNIQURE NV in Q1 2021. The put-call ratio across all filers is 0.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $414,741 | +637963.1% | 828,201 | +14460.5% | 1.06% | – |
Q2 2023 | $65 | -43.5% | 5,688 | 0.0% | 0.00% | -100.0% |
Q1 2023 | $115 | -10.9% | 5,688 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $129 | -99.9% | 5,688 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $107,000 | +0.9% | 5,688 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $106,000 | +2.9% | 5,688 | 0.0% | 0.00% | – |
Q1 2022 | $103,000 | -12.7% | 5,688 | 0.0% | 0.00% | – |
Q4 2021 | $118,000 | -35.2% | 5,688 | 0.0% | 0.00% | -100.0% |
Q3 2021 | $182,000 | +4.0% | 5,688 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $175,000 | -8.9% | 5,688 | 0.0% | 0.00% | 0.0% |
Q1 2021 | $192,000 | -6.8% | 5,688 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $206,000 | -1.4% | 5,688 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $209,000 | -18.4% | 5,688 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $256,000 | -5.2% | 5,688 | 0.0% | 0.00% | -50.0% |
Q1 2020 | $270,000 | -31.3% | 5,688 | +3.7% | 0.00% | 0.0% |
Q4 2019 | $393,000 | +81.9% | 5,487 | 0.0% | 0.00% | +100.0% |
Q3 2019 | $216,000 | – | 5,487 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aquilo Capital Management, LLC | 841,471 | $15,786,000 | 5.69% |
Nantahala Capital Management | 2,901,929 | $54,440,000 | 3.52% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 544,500 | $10,209,000 | 3.27% |
683 Capital Management, LLC | 1,373,600 | $25,768,000 | 1.99% |
PFM Health Sciences, LP | 2,393,311 | $44,899,000 | 1.62% |
Integral Health Asset Management, LLC | 433,000 | $8,123,000 | 1.58% |
Privium Fund Management B.V. | 238,998 | $4,283,000 | 1.56% |
Nantahala Capital Management | 1,000,000 | $18,760,000 | 1.21% |
Henry James International Management Inc. | 89,469 | $1,678,000 | 0.94% |
Altium Capital Management LP | 105,000 | $1,970,000 | 0.72% |